Understand the source comparison
Animal Studies vs Human Trials Peptide Research: Key Differences Comparison
Primary Purpose Establish mechanism, safety threshold, and LD50 in controlled conditions Validate clinical efficacy, measure real-world bioavailability, identify human-specific adverse events Animal data proves concept; human data proves clinical utility. Neit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Purpose
- Establish mechanism, safety threshold, and LD50 in controlled conditions
- Validate clinical efficacy, measure real-world bioavailability, identify human-specific adverse events
- Animal data proves concept; human data proves clinical utility. Neither alone is sufficient
- Regulatory Requirement
- Mandatory before any human exposure (FDA 21 CFR Part 312)
- Required for market approval and therapeutic claims
- You can't skip animal work, and you can't stop at it
- Participant Homogeneity
- Inbred strains, identical genetics, controlled diet and environment
- Genetic diversity, varied baseline health, unpredictable co-medications and lifestyle factors
- Animal models reduce noise but sacrifice real-world applicability
- Dose Scaling Method
- mg/kg body weight with allometric scaling factors
- Flat dosing or weight-based with human-specific PK modeling
- Direct mg/kg conversion from mice to humans overestimates required human dose by 7–12×
- Cost Per Study
- $50,000–$300,000 for rodent studies; $500,000–$2M for primate studies
- Phase 1: $1–5M; Phase 2: $10–30M; Phase 3: $50–150M
- The cost jump from preclinical to Phase 3 is why 90% of peptides never reach market
- Timeline
- 6–18 months for full preclinical package
- Phase 1: 12–18 months; Phase 2: 18–36 months; Phase 3: 24–48 months
- Total bench-to-approval timeline for a successful peptide: 8–12 years